JACC: In patients with documented hypersensitivity reactions after DES implantation, the reaction could be due either to medical therapy associated with stent implantation or to the DES itself. Several components of the DES could be responsible for the hypersensitivity reaction. These include the polymer coating, the drug (rapamycin for CYPHER and paclitaxel for TAXUS), or the stent itself.
Of particular importance for the clinician is the hypersensitivity reaction to the commonly prescribed thienopyridine antiplatelet agent clopidogrel (plavix), which occurs in 5% of patients. The most common presentation is rash; more serious hypersensitivity reactions requiring treatment with corticosteroids are rare.
Hope this information helps. Take cae and thanks for sharing.